Charles Schwab
SNDX icon

Charles Schwab’s Syndax Pharmaceuticals SNDX Stock Holding History

Charles Schwab’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8M Buy
814,303
+99,150
+14% +$2.06M ﹤0.01% 1889
2026
Q1 		$16.7M Sell
715,153
-12,271
-2% -$267K ﹤0.01% 1846
2025
Q4 		$15.3M Buy
727,424
+8,390
+1% +$146K ﹤0.01% 1914
2025
Q3 		$11.1M Buy
719,034
+6,724
+0.9% +$88K ﹤0.01% 2067
2025
Q2 		$6.67M Buy
712,310
+22,617
+3% +$249K ﹤0.01% 2205
2025
Q1 		$8.47M Sell
689,693
-15,130
-2% -$213K ﹤0.01% 2029
2024
Q4 		$9.32M Buy
704,823
+8,876
+1% +$152K ﹤0.01% 2046
2024
Q3 		$13.4M Buy
695,947
+41,458
+6% +$857K ﹤0.01% 1898
2024
Q2 		$13.4M Buy
654,489
+19,282
+3% +$404K ﹤0.01% 1890
2024
Q1 		$15.1M Buy
635,207
+58,185
+10% +$1.3M ﹤0.01% 1770
2023
Q4 		$12.5M Buy
577,022
+70,555
+14% +$1.08M ﹤0.01% 1872
2023
Q3 		$7.35M Buy
506,467
+15,156
+3% +$287K ﹤0.01% 2078
2023
Q2 		$10.3M Buy
491,311
+21,145
+4% +$440K ﹤0.01% 1896
2023
Q1 		$9.93M Buy
470,166
+21,425
+5% +$533K ﹤0.01% 1879
2022
Q4 		$11.4M Buy
448,741
+63,620
+17% +$1.48M ﹤0.01% 1786
2022
Q3 		$9.26M Buy
385,121
+28,216
+8% +$633K ﹤0.01% 1882
2022
Q2 		$6.87M Buy
356,905
+15,601
+5% +$260K ﹤0.01% 2030
2022
Q1 		$5.93M Buy
341,304
+35,308
+12% +$595K ﹤0.01% 2200
2021
Q4 		$6.7M Buy
305,996
+3,469
+1% +$64.1K ﹤0.01% 2204
2021
Q3 		$5.78M Buy
302,527
+32,896
+12% +$548K ﹤0.01% 2303
2021
Q2 		$4.63M Buy
269,631
+38,698
+17% +$709K ﹤0.01% 2389
2021
Q1 		$5.16M Buy
230,933
+36,465
+19% +$824K ﹤0.01% 2290
2020
Q4 		$4.33M Buy
194,468
+10,900
+6% +$226K ﹤0.01% 2295
2020
Q3 		$2.71M Buy
183,568
+117,149
+176% +$1.79M ﹤0.01% 2382
2020
Q2 		$985K Buy
66,419
+10,661
+19% +$162K ﹤0.01% 2632
2020
Q1 		$612K Buy
55,758
+5,594
+11% +$52.5K ﹤0.01% 2643
2019
Q4 		$441K Hold
50,164
– – ﹤0.01% 2868
2019
Q3 		$375K Hold
50,164
– – ﹤0.01% 2909
2019
Q2 		$468K Buy
50,164
+12,947
+35% +$94.4K ﹤0.01% 2844
2019
Q1 		$196K Buy
37,217
+8,335
+29% +$47.5K ﹤0.01% 3026
2018
Q4 		$129K Buy
28,882
+4,700
+19% +$25.8K ﹤0.01% 3072
2018
Q3 		$196K Sell
24,182
-218
-0.9% -$1.55K ﹤0.01% 3079
2018
Q2 		$172K Hold
24,400
– – ﹤0.01% 3078
2018
Q1 		$348K Hold
24,400
– – ﹤0.01% 2835
2017
Q4 		$214K Hold
24,400
– – ﹤0.01% 2971
2017
Q3 		$286K Buy
24,400
+14,300
+142% +$175K ﹤0.01% 2888
2017
Q2 		$142K Hold
10,100
– – ﹤0.01% 3071
2017
Q1 		$139K Hold
10,100
– – ﹤0.01% 2978
2016
Q4 		$73K Hold
10,100
– – ﹤0.01% 3059
2016
Q3 		$154K Hold
10,100
– – ﹤0.01% 2966
2016
Q2 		$100K Buy
+10,100
New +$138K ﹤0.01% 3054

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Charles Schwab's SNDX Position: Q2 2026 in Review

Charles Schwab increased its Syndax Pharmaceuticals (SNDX) stake by 14% in Q2 2026, buying an estimated $2.06M and bringing the position to 814,303 shares worth $17.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1889.

Charles Schwab first reported a position in SNDX in Q2 2016 and has held it in 41 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Charles Schwab held 814,303 shares of Syndax Pharmaceuticals worth $17.8M as of Q2 2026.
  • Charles Schwab bought 99,150 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.06M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1889 holding.
  • Charles Schwab first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.